HC Wainwright reiterated their buy rating on shares of Sensus Healthcare (NASDAQ:SRTS) in a report issued on Thursday, AnalystRatings.com reports. The brokerage currently has a $10.00 price target on the stock.
Several other equities research analysts also recently weighed in on SRTS. ValuEngine downgraded Sensus Healthcare from a buy rating to a hold rating in a report on Thursday, October 17th. Maxim Group set a $11.00 price target on Sensus Healthcare and gave the stock a buy rating in a report on Friday, August 9th. Finally, TheStreet upgraded Sensus Healthcare from a d+ rating to a c- rating in a report on Monday, August 26th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of Hold and an average target price of $8.30.
Sensus Healthcare stock traded down $0.21 during midday trading on Thursday, reaching $3.80. 73,900 shares of the stock traded hands, compared to its average volume of 31,014. The stock’s fifty day moving average is $5.73 and its 200-day moving average is $5.72. Sensus Healthcare has a 12 month low of $3.71 and a 12 month high of $9.23. The stock has a market cap of $93.54 million, a P/E ratio of -27.14 and a beta of -0.41.
Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.01. Sensus Healthcare had a negative return on equity of 8.82% and a negative net margin of 8.65%. The firm had revenue of $5.84 million for the quarter, compared to the consensus estimate of $7.77 million. As a group, research analysts predict that Sensus Healthcare will post -0.12 EPS for the current fiscal year.
A number of large investors have recently made changes to their positions in SRTS. Wells Fargo & Company MN bought a new position in Sensus Healthcare in the second quarter worth approximately $30,000. Heartland Advisors Inc. grew its stake in Sensus Healthcare by 150.0% in the second quarter. Heartland Advisors Inc. now owns 375,000 shares of the company’s stock worth $2,078,000 after purchasing an additional 225,000 shares in the last quarter. BlackRock Inc. grew its stake in Sensus Healthcare by 40.7% in the second quarter. BlackRock Inc. now owns 103,643 shares of the company’s stock worth $574,000 after purchasing an additional 29,990 shares in the last quarter. Susquehanna International Group LLP grew its stake in Sensus Healthcare by 69.9% in the second quarter. Susquehanna International Group LLP now owns 27,492 shares of the company’s stock worth $152,000 after purchasing an additional 11,311 shares in the last quarter. Finally, Essex Investment Management Co. LLC bought a new position in Sensus Healthcare in the third quarter worth approximately $540,000. 9.95% of the stock is currently owned by institutional investors.
Sensus Healthcare Company Profile
Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Read More: Intrinsic Value and Stock Selection
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.